Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
NUTX vs UHS vs HCA vs THC vs CYH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
NUTX vs UHS vs HCA vs THC vs CYH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $801M | $10.68B | $95.95B | $17.01B | $408M |
| Revenue (TTM) | $880M | $17.76B | $75.60B | $21.45B | $21.48B |
| Net Income (TTM) | $96M | $1.52B | $6.78B | $1.70B | $-88M |
| Gross Margin | 47.5% | 67.6% | 41.5% | 42.8% | 53.7% |
| Operating Margin | 31.4% | 11.5% | 15.8% | 16.1% | -39.8% |
| Forward P/E | 8.7x | 7.3x | 14.2x | 10.9x | 0.8x |
| Total Debt | $351M | $5.51B | $50.20B | $13.17B | $11.58B |
| Cash & Equiv. | $186M | $138M | $1.04B | $2.88B | $260M |
NUTX vs UHS vs HCA vs THC vs CYH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 22 | May 26 | Return |
|---|---|---|---|
| Nutex Health, Inc. (NUTX) | 100 | 9.5 | -90.5% |
| Universal Health Se… (UHS) | 100 | 139.2 | +39.2% |
| HCA Healthcare, Inc. (HCA) | 100 | 200.0 | +100.0% |
| Tenet Healthcare Co… (THC) | 100 | 267.7 | +167.7% |
| Community Health Sy… (CYH) | 100 | 37.7 | -62.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NUTX vs UHS vs HCA vs THC vs CYH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NUTX is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 82.4%, EPS growth 7.9%, 3Y rev CAGR 58.6%
- 82.4% revenue growth vs CYH's -1.2%
- 11.0% margin vs CYH's -0.4%
UHS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.60, Low D/E 74.3%, current ratio 1.05x
HCA carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 5 yrs, beta 0.29, yield 0.7%
- Beta 0.29, yield 0.7%, current ratio 0.83x
- Beta 0.29 vs NUTX's 2.01
- 0.7% yield, 5-year raise streak, vs UHS's 0.5%, (3 stocks pay no dividend)
THC ranks third and is worth considering specifically for long-term compounding and valuation efficiency.
- 5.2% 10Y total return vs HCA's 450.5%
- PEG 0.33 vs HCA's 0.67
- +27.4% vs CYH's -11.7%
CYH is the clearest fit if your priority is value.
- Lower P/E (0.8x vs 14.2x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 82.4% revenue growth vs CYH's -1.2% | |
| Value | Lower P/E (0.8x vs 14.2x) | |
| Quality / Margins | 11.0% margin vs CYH's -0.4% | |
| Stability / Safety | Beta 0.29 vs NUTX's 2.01 | |
| Dividends | 0.7% yield, 5-year raise streak, vs UHS's 0.5%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +27.4% vs CYH's -11.7% | |
| Efficiency (ROA) | 11.3% ROA vs CYH's -0.7%, ROIC 19.9% vs -70.1% |
NUTX vs UHS vs HCA vs THC vs CYH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
NUTX vs UHS vs HCA vs THC vs CYH — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NUTX leads in 2 of 6 categories
CYH leads 1 • THC leads 1 • HCA leads 1 • UHS leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NUTX leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 85.9x NUTX's $880M. NUTX is the more profitable business, keeping 11.0% of every revenue dollar as net income compared to CYH's -0.4%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $880M | $17.8B | $75.6B | $21.5B | $21.5B |
| EBITDAEarnings before interest/tax | $297M | $2.7B | $15.5B | $4.3B | -$7.8B |
| Net IncomeAfter-tax profit | $96M | $1.5B | $6.8B | $1.7B | -$88M |
| Free Cash FlowCash after capex | $270M | $894M | $7.7B | $3.3B | -$200M |
| Gross MarginGross profit ÷ Revenue | +47.5% | +67.6% | +41.5% | +42.8% | +53.7% |
| Operating MarginEBIT ÷ Revenue | +31.4% | +11.5% | +15.8% | +16.1% | -39.8% |
| Net MarginNet income ÷ Revenue | +11.0% | +8.6% | +9.0% | +7.9% | -0.4% |
| FCF MarginFCF ÷ Revenue | +30.7% | +5.0% | +10.2% | +15.6% | -0.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.2% | +9.6% | +6.7% | +2.8% | +2.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +154.7% | +17.7% | +44.6% | +87.6% | -45.2% |
Valuation Metrics
CYH leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 0.8x trailing earnings, CYH trades at a 95% valuation discount to HCA's 15.1x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.38x vs HCA's 0.72x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $801M | $10.7B | $95.9B | $17.0B | $408M |
| Enterprise ValueMkt cap + debt − cash | $967M | $16.0B | $145.1B | $27.3B | $11.7B |
| Trailing P/EPrice ÷ TTM EPS | 12.84x | 7.38x | 15.12x | 12.53x | 0.77x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.73x | 7.30x | 14.19x | 10.94x | — |
| PEG RatioP/E ÷ EPS growth rate | — | 0.46x | 0.72x | 0.38x | — |
| EV / EBITDAEnterprise value multiple | 3.27x | 6.14x | 9.37x | 6.34x | — |
| Price / SalesMarket cap ÷ Revenue | 0.92x | 0.61x | 1.27x | 0.80x | 0.03x |
| Price / BookPrice ÷ Book value/share | 2.15x | 1.48x | — | 1.97x | — |
| Price / FCFMarket cap ÷ FCF | 3.26x | 12.57x | 12.47x | 6.72x | 1.96x |
Profitability & Efficiency
NUTX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
NUTX delivers a 22.2% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $20 for THC. UHS carries lower financial leverage with a 0.74x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), NUTX scores 7/9 vs CYH's 6/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +22.2% | +20.7% | — | +19.6% | — |
| ROA (TTM)Return on assets | +10.5% | +9.8% | +11.3% | +5.7% | -0.7% |
| ROICReturn on invested capital | +38.0% | +12.3% | +19.9% | +13.2% | -70.1% |
| ROCEReturn on capital employed | +43.2% | +16.0% | +27.0% | +13.8% | -87.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 | 7 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.83x | 0.74x | — | 1.47x | — |
| Net DebtTotal debt minus cash | $166M | $5.4B | $49.2B | $10.3B | $11.3B |
| Cash & Equiv.Liquid assets | $186M | $138M | $1.0B | $2.9B | $260M |
| Total DebtShort + long-term debt | $351M | $5.5B | $50.2B | $13.2B | $11.6B |
| Interest CoverageEBIT ÷ Interest expense | 9.13x | 10.92x | 5.37x | 4.28x | 4.89x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,044 today (with dividends reinvested), compared to $224 for NUTX. Over the past 12 months, THC leads with a +27.4% total return vs CYH's -11.7%. The 3-year compound annual growth rate (CAGR) favors THC at 40.7% vs CYH's -6.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.2% | -22.3% | -8.6% | -2.7% | -6.6% |
| 1-Year ReturnPast 12 months | +14.6% | -8.2% | +19.7% | +27.4% | -11.7% |
| 3-Year ReturnCumulative with dividends | +74.8% | +20.8% | +57.4% | +178.5% | -16.8% |
| 5-Year ReturnCumulative with dividends | -97.8% | +12.5% | +109.7% | +190.4% | -81.0% |
| 10-Year ReturnCumulative with dividends | -97.8% | +30.8% | +450.5% | +523.4% | -80.3% |
| CAGR (3Y)Annualised 3-year return | +20.5% | +6.5% | +16.3% | +40.7% | -6.0% |
Risk & Volatility
Evenly matched — HCA and THC each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than NUTX's 2.01 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. THC currently trades 78.5% from its 52-week high vs CYH's 64.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.01x | 0.60x | 0.29x | 0.71x | 1.60x |
| 52-Week HighHighest price in past year | $193.07 | $246.33 | $556.52 | $247.21 | $4.47 |
| 52-Week LowLowest price in past year | $77.21 | $152.33 | $330.00 | $146.60 | $2.38 |
| % of 52W HighCurrent price vs 52-week peak | +69.7% | +69.2% | +77.1% | +78.5% | +64.8% |
| RSI (14)Momentum oscillator 0–100 | 59.7 | 39.7 | 30.8 | 52.9 | 46.4 |
| Avg Volume (50D)Average daily shares traded | 197K | 793K | 1000K | 1.2M | 1.6M |
Analyst Outlook
HCA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NUTX as "Buy", UHS as "Hold", HCA as "Buy", THC as "Buy", CYH as "Hold". Consensus price targets imply 52.3% upside for NUTX (target: $205) vs 1.2% for CYH (target: $3). For income investors, HCA offers the higher dividend yield at 0.69% vs UHS's 0.47%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $205.00 | $231.50 | $527.45 | $268.00 | $2.93 |
| # AnalystsCovering analysts | 2 | 43 | 46 | 32 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% | +0.7% | — | — |
| Dividend StreakConsecutive years of raises | 1 | 1 | 5 | 0 | 2 |
| Dividend / ShareAnnual DPS | — | $0.80 | $2.94 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +9.1% | +10.5% | +8.4% | +0.5% |
NUTX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CYH leads in 1 (Valuation Metrics). 1 tied.
NUTX vs UHS vs HCA vs THC vs CYH: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NUTX or UHS or HCA or THC or CYH a better buy right now?
For growth investors, Nutex Health, Inc.
(NUTX) is the stronger pick with 82. 4% revenue growth year-over-year, versus -1. 2% for Community Health Systems, Inc. (CYH). Community Health Systems, Inc. (CYH) offers the better valuation at 0. 8x trailing P/E, making it the more compelling value choice. Analysts rate Nutex Health, Inc. (NUTX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NUTX or UHS or HCA or THC or CYH?
On trailing P/E, Community Health Systems, Inc.
(CYH) is the cheapest at 0. 8x versus HCA Healthcare, Inc. at 15. 1x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NUTX or UHS or HCA or THC or CYH?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.
4%, compared to -97. 8% for Nutex Health, Inc. (NUTX). Over 10 years, the gap is even starker: THC returned +523. 4% versus NUTX's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NUTX or UHS or HCA or THC or CYH?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 29β versus Nutex Health, Inc. 's 2. 01β — meaning NUTX is approximately 603% more volatile than HCA relative to the S&P 500. On balance sheet safety, Universal Health Services, Inc. (UHS) carries a lower debt/equity ratio of 74% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — NUTX or UHS or HCA or THC or CYH?
By revenue growth (latest reported year), Nutex Health, Inc.
(NUTX) is pulling ahead at 82. 4% versus -1. 2% for Community Health Systems, Inc. (CYH). On earnings-per-share growth, the picture is similar: Community Health Systems, Inc. grew EPS 196. 7% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, NUTX leads at 58. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NUTX or UHS or HCA or THC or CYH?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus 4. 1% for Community Health Systems, Inc. — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NUTX leads at 31. 5% versus -79. 4% for CYH. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NUTX or UHS or HCA or THC or CYH more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Universal Health Services, Inc. (UHS) trades at 7. 3x forward P/E versus 14. 2x for HCA Healthcare, Inc. — 6. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUTX: 52. 3% to $205. 00.
08Which pays a better dividend — NUTX or UHS or HCA or THC or CYH?
In this comparison, HCA (0.
7% yield), UHS (0. 5% yield) pay a dividend. NUTX, THC, CYH do not pay a meaningful dividend and should not be held primarily for income.
09Is NUTX or UHS or HCA or THC or CYH better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Nutex Health, Inc. (NUTX) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCA: +450. 5%, NUTX: -97. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NUTX and UHS and HCA and THC and CYH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NUTX is a small-cap high-growth stock; UHS is a mid-cap deep-value stock; HCA is a mid-cap deep-value stock; THC is a mid-cap deep-value stock; CYH is a small-cap deep-value stock. HCA pays a dividend while NUTX, UHS, THC, CYH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.